Chikungunya fever.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
06 04 2023
06 04 2023
Historique:
accepted:
10
03
2023
medline:
10
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Chikungunya virus is widespread throughout the tropics, where it causes recurrent outbreaks of chikungunya fever. In recent years, outbreaks have afflicted populations in East and Central Africa, South America and Southeast Asia. The virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Chikungunya fever is characterized by severe arthralgia and myalgia that can persist for years and have considerable detrimental effects on health, quality of life and economic productivity. The effects of climate change as well as increased globalization of commerce and travel have led to growth of the habitat of Aedes mosquitoes. As a result, increasing numbers of people will be at risk of chikungunya fever in the coming years. In the absence of specific antiviral treatments and with vaccines still in development, surveillance and vector control are essential to suppress re-emergence and epidemics.
Identifiants
pubmed: 37024497
doi: 10.1038/s41572-023-00429-2
pii: 10.1038/s41572-023-00429-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Springer Nature Limited.
Références
Kramer, I. M. et al. The ecophysiological plasticity of Aedes aegypti and Aedes albopictus concerning overwintering in cooler ecoregions is driven by local climate and acclimation capacity. Sci. Total. Environ. 778, 146128 (2021).
pubmed: 34030376
doi: 10.1016/j.scitotenv.2021.146128
Laporta, G. Z. et al. Global distribution of Aedes aegypti and Aedes albopictus in a climate change scenario of regional rivalry. Insects 14, 49 (2023).
pubmed: 36661976
pmcid: 9860750
doi: 10.3390/insects14010049
Mercier, A. et al. Impact of temperature on dengue and chikungunyatransmission by the mosquito Aedes albopictus. Sci. Rep. 12, 6973 (2022).
pubmed: 35484193
pmcid: 9051100
doi: 10.1038/s41598-022-10977-4
Zaid, A. et al. Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet Infect. Dis. 21, e123–e133 (2021). This review focuses on CHIKV and other arthritogenic alphaviruses that have been identified globally, and provides a comprehensive appraisal of present and future research directions.
pubmed: 33160445
doi: 10.1016/S1473-3099(20)30491-6
Weaver, S. C., Chen, R. & Diallo, M. Chikungunya virus: role of vectors in emergence from enzootic cycles. Annu. Rev. Entomol. 65, 313–332 (2020).
pubmed: 31594410
doi: 10.1146/annurev-ento-011019-025207
Azar, S. R., Campos, R. K., Bergren, N. A., Camargos, V. N. & Rossi, S. L. Epidemic alphaviruses: ecology, emergence and outbreaks. Microorganisms 8, 1167 (2020).
pubmed: 32752150
pmcid: 7464724
doi: 10.3390/microorganisms8081167
CEPI. Priority diseases. CEPI https://cepi.net/research_dev/priority-diseases/ (2017).
Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir. Res. 159, 63–67 (2018).
pubmed: 30261226
doi: 10.1016/j.antiviral.2018.09.009
Kril, V., Aïqui-Reboul-Paviet, O., Briant, L. & Amara, A. New insights into chikungunya virus infection and pathogenesis. Annu. Rev. Virol. 8, 327–347 (2021).
pubmed: 34255544
doi: 10.1146/annurev-virology-091919-102021
Longbottom, J. et al. Aedes albopictus invasion across Africa: the time is now for cross-country collaboration and control. Lancet Glob. Health https://doi.org/10.1016/S2214-109X(23)00046-3 (2023).
doi: 10.1016/S2214-109X(23)00046-3
pubmed: 36841255
Kolimenakis, A. et al. The role of urbanisation in the spread of Aedes mosquitoes and the diseases they transmit — a systematic review. PLoS Negl. Trop. Dis. 15, e0009631 (2021).
pubmed: 34499653
pmcid: 8428665
doi: 10.1371/journal.pntd.0009631
Sharif, N. et al. Molecular epidemiology, evolution and reemergence of chikungunya virus in South Asia. Front. Microbiol. 12, 689979 (2021).
pubmed: 34163459
pmcid: 8215147
doi: 10.3389/fmicb.2021.689979
Gloria-Soria, A. et al. Vector competence of Aedes albopictus populations from the northeasters United States for Chikungunya, Dengue, and Zika Viruses. Am. J. Trop. Med. Hyg. 104, 1123–1130 (2020).
pubmed: 33355070
pmcid: 7941830
de Lima Cavalcanti, T. Y. V., Pereira, M. R., de Paula, S. O. & Franca, R. F. O. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses 14, 969 (2022).
pubmed: 35632709
pmcid: 9147731
doi: 10.3390/v14050969
Powers, A. M., Brault, A. C., Tesh, R. B. & Weaver, S. C. Re-emergence of Chikungunya and O’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81, 471–479 (2000).
pubmed: 10644846
Schuffenecker, I. et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3, e263 (2006).
pubmed: 16700631
pmcid: 1463904
doi: 10.1371/journal.pmed.0030263
Volk, S. M. et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J. Virol. 84, 6497–6504 (2010).
pubmed: 20410280
pmcid: 2903258
doi: 10.1128/JVI.01603-09
Selhorst, P. et al. Molecular characterization of chikungunya virus during the 2019 outbreak in the Democratic Republic of the Congo. Emerg. Microbes Infect. 9, 1912–1918 (2020).
pubmed: 32787529
pmcid: 8284967
doi: 10.1080/22221751.2020.1810135
Kariuki Njenga, M. et al. Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. J. Gen. Virol. 89, 2754–2760 (2008).
pubmed: 18931072
pmcid: 3347796
doi: 10.1099/vir.0.2008/005413-0
Sergon, K. et al. Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am. J. Trop. Med. Hyg. 78, 333–337 (2008).
pubmed: 18256441
doi: 10.4269/ajtmh.2008.78.333
Chretien, J. P. et al. Drought-associated chikungunya emergence along coastal East Africa. Am. J. Trop. Med. Hyg. 76, 405–407 (2007).
pubmed: 17360859
doi: 10.4269/ajtmh.2007.76.405
Gérardin, P. et al. Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect. Dis. 8, 99 (2008).
pubmed: 18662384
pmcid: 2528011
doi: 10.1186/1471-2334-8-99
Josseran, L. et al. Chikungunya disease outbreak, Reunion Island. Emerg. Infect. Dis. 12, 1994–1995 (2006).
pubmed: 17354339
pmcid: 3291364
doi: 10.3201/eid1212.060710
Powers, A. M. & Logue, C. H. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J. Gen. Virol. 88, 2363–2377 (2007).
pubmed: 17698645
doi: 10.1099/vir.0.82858-0
Arankalle, V. A. et al. Genetic divergence of Chikungunya viruses in India (1963–2006) with special reference to the 2005–2006 explosive epidemic. J. Gen. Virol. 88, 1967–1976 (2007).
pubmed: 17554030
doi: 10.1099/vir.0.82714-0
Angelini, P. et al. Chikungunya epidemic outbreak in Emilia-Romagna (Italy) during summer 2007. Parassitologia 50, 97–98 (2008).
pubmed: 18693568
Delisle, E. et al. Chikungunya outbreak in Montpellier, France, September to October 2014. Eurosurveillance 20, 21108 (2015).
pubmed: 25955774
doi: 10.2807/1560-7917.ES2015.20.17.21108
Cassadou, S. et al. Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. Eurosurveillance 19, 20752 (2014).
pubmed: 24721536
doi: 10.2807/1560-7917.ES2014.19.13.20752
Van Bortel, W. et al. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Eurosurveillance 19, 20759 (2014).
pubmed: 24721539
de Oliveira, E. C. et al. Short report: Introduction of chikungunya virus ECSA genotype into the Brazilian Midwest and its dispersion through the Americas. PLoS Negl. Trop. Dis. 15, e0009290 (2021).
pubmed: 33861753
pmcid: 8051810
doi: 10.1371/journal.pntd.0009290
Tsetsarkin, K. A., Vanlandingham, D. L., McGee, C. E. & Higgs, S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3, e201 (2007). This paper demonstrated that the E1-A226V mutation was directly responsible for a significant increase in CHIKV infectivity for Ae. albopictus and led to more efficient viral dissemination into mosquito secondary organs and transmission to suckling mice.
pubmed: 18069894
pmcid: 2134949
doi: 10.1371/journal.ppat.0030201
Tsetsarkin, K. A., Chen, R. & Weaver, S. C. Interspecies transmission and chikungunya virus emergence. Curr. Opin. Virol. 16, 143–150 (2016).
pubmed: 26986235
pmcid: 4824623
doi: 10.1016/j.coviro.2016.02.007
Tsetsarkin, K. A. et al. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc. Natl Acad. Sci. USA 108, 7872–7877 (2011).
pubmed: 21518887
pmcid: 3093459
doi: 10.1073/pnas.1018344108
Tsetsarkin, K. A. & Weaver, S. C. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog. 7, e1002412 (2011).
pubmed: 22174678
pmcid: 3234230
doi: 10.1371/journal.ppat.1002412
Tsetsarkin, K. A. et al. Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS ONE 4, e6835 (2009).
pubmed: 19718263
pmcid: 2729410
doi: 10.1371/journal.pone.0006835
Weaver, S. C., Forrester, N. L., Liu, J. & Vasilakis, N. Population bottlenecks and founder effects: implications for mosquito-borne arboviral emergence. Nat. Rev. Microbiol. 19, 184–195 (2021). This review discusses the role of genetic drift following population bottlenecks and founder effects in arboviral evolution and spread, and the emergence of human disease.
pubmed: 33432235
pmcid: 7798019
doi: 10.1038/s41579-020-00482-8
Nsoesie, E. O. et al. Global distribution and environmental suitability for chikungunya virus 1952 to 2015. Eurosurveillance 21, https://doi.org/10.2807/1560-7917.ES.2016.21.20.30234 (2016).
Leta, S. et al. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. Int. J. Infect. Dis. 67, 25–35 (2018).
pubmed: 29196275
doi: 10.1016/j.ijid.2017.11.026
Mora, C. et al. Over half of known human pathogenic diseases can be aggravated by climate change. Nat. Clim. Change 12, 869–875 (2022).
doi: 10.1038/s41558-022-01426-1
Tjaden, N. B. et al. Modelling the effects of global climate change on Chikungunya transmission in the 21
pubmed: 28630444
pmcid: 5476675
doi: 10.1038/s41598-017-03566-3
Dorléans, F. et al. Outbreak of Chikungunya in the French Caribbean islands of Martinique and Guadeloupe: findings from a hospital-based surveillance system (2013-2015). Am. J. Trop. Med. Hyg. 98, 1819–1825 (2018).
pubmed: 29692295
pmcid: 6086161
doi: 10.4269/ajtmh.16-0719
Sharp, T. M. et al. Centers for disease control and prevention (CDC). Chikungunya cases identified through passive surveillance and household investigation — Puerto Rico, May 5-August 12, 2014. MMWR Morb. Mortal. Wkly Rep. 63, 1121–1128 (2014).
pubmed: 25474032
pmcid: 4584601
Silva Junior, G. B. D., Pinto, J. R., Mota, R. M. S., Pires Neto, R. D. J. & Daher, E. F. Impact of chronic kidney disease on chikungunya virus infection clinical manifestations and outcome: highlights during an outbreak in northeastern Brazil. Am. J. Trop. Med. Hyg. 99, 1327–1330 (2018).
pubmed: 30226152
pmcid: 6221237
doi: 10.4269/ajtmh.18-0531
Soumahoro, M. K. et al. The Chikungunya epidemic on La Réunion Island in 2005-2006: a cost-of-illness study. PLoS Negl. Trop. Dis. 5, e1197 (2011).
pubmed: 21695162
pmcid: 3114750
doi: 10.1371/journal.pntd.0001197
Freitas, A. R. R., Alarcón-Elbal, P. M., Paulino-Ramírez, R. & Donalisio, M. R. Excess mortality profile during the Asian genotype chikungunya epidemic in the Dominican Republic, 2014. Trans. R. Soc. Trop. Med. Hyg. 112, 443–449 (2018).
pubmed: 30085307
doi: 10.1093/trstmh/try072
Jaffar-Bandjee, M. C. et al. Emergence and clinical insights into the pathology of Chikungunya virus infection. Expert Rev. Anti. Infect. Ther. 8, 987–996 (2010).
pubmed: 20818943
doi: 10.1586/eri.10.92
Brito, C. A. A. Alert: severe cases and deaths associated with Chikungunya in Brazil. Rev. Soc. Bras. Med. Trop. 50, 585–589 (2017).
pubmed: 29160503
doi: 10.1590/0037-8682-0479-2016
Fred, A. et al. SEROCHIK group. Individual and contextual risk factors for chikungunya virus infection: the SEROCHIK cross-sectional population-based study. Epidemiol. Infect. 146, 1056–1064 (2018).
pubmed: 29720285
doi: 10.1017/S0950268818000341
Paixão, E. S. et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans. R. Soc. Trop. Med. Hyg. 112, 301–316 (2018).
pubmed: 30007303
doi: 10.1093/trstmh/try063
Westaway, E. G. et al. Togaviridae. Intervirology 24, 125–139 (1985).
pubmed: 2999027
doi: 10.1159/000149632
Voss, J. E. et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468, 709–712 (2010).
pubmed: 21124458
doi: 10.1038/nature09555
Akahata, W. et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334–338 (2010).
pubmed: 20111039
pmcid: 2834826
doi: 10.1038/nm.2105
Mukhopadhyay, S. et al. Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure 14, 63–73 (2006).
pubmed: 16407066
pmcid: 2757649
doi: 10.1016/j.str.2005.07.025
Khan, A. H. et al. Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J. Gen. Virol. 83, 3075–3084 (2002).
pubmed: 12466484
doi: 10.1099/0022-1317-83-12-3075
Hyde, J. L. et al. The 5′ and 3′ ends of alphavirus RNA — non-coding is not non-functional. Virus Res. 206, 99–107 (2015).
pubmed: 25630058
pmcid: 4654126
doi: 10.1016/j.virusres.2015.01.016
Frolov, I. & Frolova, E. I. Molecular virology of Chikungunya virus. Curr. Top. Microbiol. Immunol. 435, 1–31 (2022). This review summarizes the current understanding of molecular mechanisms of alphavirus RNA replication and interaction with host cells. Emphasis was placed on demonstrating the distinct features of CHIKV in utilizing host factors to build replication complexes and modify the intracellular environment for efficient viral replication and inhibition of the innate immune response.
pubmed: 30599050
Ahola, T., McInerney, G. & Merits, A. Alphavirus RNA replication in vertebrate cells. Adv. Virus Res. 111, 111–156 (2021).
pubmed: 34663497
doi: 10.1016/bs.aivir.2021.07.003
Hardy, W. R. & Strauss, J. H. Processing the nonstructural polyproteins of sindbis virus: nonstructural proteinase is in the C-terminal half of nsP2 and functions both in cis and in trans. J. Virol. 63, 4653–4664 (1989).
pubmed: 2529379
pmcid: 251099
doi: 10.1128/jvi.63.11.4653-4664.1989
Tomar, S., Hardy, R. W., Smith, J. L. & Kuhn, R. J. Catalytic core of alphavirus nonstructural protein nsP4 possesses terminal adenylyltransferase activity. J. Virol. 80, 9962–9969 (2006).
pubmed: 17005674
pmcid: 1617302
doi: 10.1128/JVI.01067-06
Vasiljeva, L., Merits, A., Auvinen, P. & Kaariainen, L. Identification of a novel function of the alphavirus capping apparatus. RNA 5′ -triphosphatase activity of Nsp2. J. Biol. Chem. 275, 17281–17287 (2000).
pubmed: 10748213
doi: 10.1074/jbc.M910340199
Ahola, T. & Kaariainen, L. Reaction in alphavirus mRNA capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc. Natl Acad. Sci. USA 92, 507–511 (1995).
pubmed: 7831320
pmcid: 42770
doi: 10.1073/pnas.92.2.507
Zhang, K. et al. Molecular basis of specific viral RNA recognition and 5′-end capping by the Chikungunya virus nsP1. Cell Rep. 40, 111133 (2022).
pubmed: 35905713
doi: 10.1016/j.celrep.2022.111133
Jones, R., Bragagnolo, G., Arranz, R. & Reguera, J. Capping pores of alphavirus nsP1 gate membranous viral replication factories. Nature 589, 615–619 (2021).
pubmed: 33328629
doi: 10.1038/s41586-020-3036-8
Laakkonen, P., Auvinen, P., Kujala, P. & Kaariainen, L. Alphavirus replicase protein NSP1 induces filopodia and rearrangement of actin filaments. J. Virol. 72, 10265–10269 (1998).
pubmed: 9811773
pmcid: 110611
doi: 10.1128/JVI.72.12.10265-10269.1998
Laurent, T. et al. Architecture of the chikungunya virus replication organelle. eLife 11, e83042 (2022).
pubmed: 36259931
pmcid: 9633065
doi: 10.7554/eLife.83042
Strauss, J. H. & Strauss, E. G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58, 491–562 (1994).
pubmed: 7968923
pmcid: 372977
doi: 10.1128/mr.58.3.491-562.1994
Lemm, J. A., Rumenapf, T., Strauss, E. G., Strauss, J. H. & Rice, C. M. Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J. 13, 2925–2934 (1994).
pubmed: 7517863
pmcid: 395174
doi: 10.1002/j.1460-2075.1994.tb06587.x
Lemm, J. A. & Rice, C. M. Roles of nonstructural polyproteins and cleavage products in regulating Sindbis virus RNA replication and transcription. J. Virol. 67, 1916–1926 (1993).
pubmed: 8445717
pmcid: 240259
doi: 10.1128/jvi.67.4.1916-1926.1993
Liu, Y., Yuan, Y. & Zhang, L. Innate immune evasion by alphaviruses. Front. Immunol. 13, 1005586 (2022).
pubmed: 36172361
pmcid: 9510981
doi: 10.3389/fimmu.2022.1005586
Jones, P. H. et al. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 438, 37–49 (2013).
pubmed: 23411007
doi: 10.1016/j.virol.2013.01.010
Göertz, G. P. et al. The methyltransferase-like domain of chikungunya virus nsP2 inhibits the interferon response by promoting the nuclear export of STAT1. J. Virol. 92, e01008–e01018 (2018).
pubmed: 29925658
pmcid: 6096799
doi: 10.1128/JVI.01008-18
Fros, J. J., van der Maten, E., Vlak, J. M. & Pijlman, G. P. The C-terminal domain of chikungunya virus nsP2 independently governs viral RNA replication, cytopathicity, and inhibition of interferon signaling. J. Virol. 87, 10394–10400 (2013).
pubmed: 23864632
pmcid: 3753987
doi: 10.1128/JVI.00884-13
Fros, J. J. et al. Chikungunya virus nsP3 blocks stress granule assembly by recruitment of G3BP into cytoplasmic foci. J. Virol. 86, 10873–10879 (2012).
pubmed: 22837213
pmcid: 3457282
doi: 10.1128/JVI.01506-12
Bae, S., Lee, J. Y. & Myoung, J. Chikungunya virus nsP2 impairs MDA5/RIG-I-mediated induction of NF-κB promoter activation: a potential target for virus-specific therapeutics. J. Microbiol. Biotechnol. 30, 1801–1809 (2020).
pubmed: 33323678
pmcid: 9728393
doi: 10.4014/jmb.2012.12005
Nair, S. R., Abraham, R., Sundaram, S. & Sreekumar, E. Interferon regulated gene (IRG) expression-signature in a mouse model of chikungunya virus neurovirulence. J. Neurovirol. 23, 886–902 (2017).
pubmed: 29067635
doi: 10.1007/s13365-017-0583-3
Sanchez David, R. Y. et al. Comparative analysis of viral RNA signatures on different RIG-I-like receptors. eLife 5, e11275 (2016).
pubmed: 27011352
pmcid: 4841775
doi: 10.7554/eLife.11275
Priya, R., Patro, I. K. & Parida, M. M. TLR3 mediated innate immune response in mice brain following infection with Chikungunya virus. Virus Res. 189, 194–205 (2014).
pubmed: 24905288
doi: 10.1016/j.virusres.2014.05.010
Fros, J. J. et al. Chikungunya virus non-structural protein 2-mediated host shut-off disables the unfolded protein response. J. Gen. Virol. 96, 580–589 (2015).
pubmed: 25395592
doi: 10.1099/vir.0.071845-0
Ekchariyawat, P. et al. Inflammasome signaling pathways exert antiviral effect against Chikungunya virus in human dermal fibroblasts. Infect. Genet. Evol. 32, 401–408 (2015).
pubmed: 25847693
doi: 10.1016/j.meegid.2015.03.025
Chen, W. et al. Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nat. Microbiol. 2, 1435–1445 (2017). This paper showed that peripheral blood mononuclear cells isolated from patients with CHIKV infection had elevated NLRP3, caspase 1 and IL-18 mRNA expression and, using a mouse model of CHIKV infection, found that high NLRP3 expression was associated with peak inflammatory symptoms and that subsequent inhibition of NLRP3 activation using a small-molecule inhibitor resulted in reduced CHIKV-induced inflammation and abrogated osteoclastogenic bone loss and myositis.
pubmed: 28848230
doi: 10.1038/s41564-017-0015-4
Ozden, S. et al. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J. Biol. Chem. 283, 21899–21908 (2008).
pubmed: 18559340
doi: 10.1074/jbc.M802444200
Yap, M. L. et al. Structural studies of Chikungunya virus maturation. Proc. Natl Acad. Sci. USA 114, 13703–13707 (2017).
pubmed: 29203665
pmcid: 5748190
doi: 10.1073/pnas.1713166114
Basore, K. et al. Cryo-EM structure of Chikungunya virus in complex with the Mxra8 receptor. Cell 177, 1725–1737.e16 (2019).
pubmed: 31080061
pmcid: 7227486
doi: 10.1016/j.cell.2019.04.006
Holmes, A. C., Basore, K., Fremont, D. H. & Diamond, M. S. A molecular understanding of alphavirus entry. PLoS Pathog. 16, e1008876 (2020).
pubmed: 33091085
pmcid: 7580943
doi: 10.1371/journal.ppat.1008876
De Caluwe, L., Arien, K. K. & Bartholomeeusen, K. Host factors and pathways involved in the entry of mosquito-borne alphaviruses. Trends Microbiol. 29, 634–647 (2021). This review summarizes the most important virus–host interactions during the early events of the alphavirus replication cycle.
pubmed: 33208275
doi: 10.1016/j.tim.2020.10.011
Jose, J., Snyder, J. E. & Kuhn, R. J. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol. 4, 837–856 (2009).
pubmed: 19722838
doi: 10.2217/fmb.09.59
Brown, R. S., Anastasakis, D. G., Hafner, M. & Kielian, M. Multiple capsid protein binding sites mediate selective packaging of the alphavirus genomic RNA. Nat. Commun. 11, 4693 (2020).
pubmed: 32943634
pmcid: 7499256
doi: 10.1038/s41467-020-18447-z
Kielian, M., Chanel-Vos, C. & Liao, M. Alphavirus entry and membrane fusion. Viruses 2, 796–825 (2010).
pubmed: 21546978
pmcid: 3086016
doi: 10.3390/v2040796
Ramsey, J. & Mukhopadhyay, S. Disentangling the frames, the state of research on the alphavirus 6K and TF proteins. Viruses 9, 228 (2017).
pubmed: 28820485
pmcid: 5580485
doi: 10.3390/v9080228
van Duijl-Richter, M. K. S., Blijleven, J. S., van Oijen, A. M. & Smit, J. M. Chikungunya virus fusion properties elucidated by single-particle and bulk approaches. J. Gen. Virol. 96, 2122–2132 (2015).
pubmed: 25872739
doi: 10.1099/vir.0.000144
Hoornweg, T. E. et al. Dynamics of chikungunya virus cell entry unraveled by single-virus tracking in living cells. J. Virol. 90, 4745–4756 (2016).
pubmed: 26912616
pmcid: 4836339
doi: 10.1128/JVI.03184-15
Zhang, R. et al. Mxra8 is a receptor for multiple arthritogenic alphaviruses. Nature 557, 570–574 (2018). This paper reports on the identification of the cell adhesion molecule MXRA8 as an entry mediator for multiple emerging arthritogenic alphaviruses, including CHIKV, Ross River virus, Mayaro virus and ONNV, using a genome-wide CRISPR–Cas9-based screen.
pubmed: 29769725
pmcid: 5970976
doi: 10.1038/s41586-018-0121-3
Zhang, R. et al. Expression of the Mxra8 receptor promotes alphavirus infection and pathogenesis in mice and Drosophila. Cell Rep. 28, 2647–2658.e5 (2019).
pubmed: 31484075
pmcid: 6745702
doi: 10.1016/j.celrep.2019.07.105
Wintachai, P. et al. Identification of prohibitin as a Chikungunya virus receptor protein. J. Med. Virol. 84, 1757–1770 (2012).
pubmed: 22997079
doi: 10.1002/jmv.23403
De Caluwe, L. et al. The CD147 protein complex is involved in entry of Chikungunya virus and related alphaviruses in human cells. Front. Microbiol. 12, 615165 (2021).
pubmed: 33717005
pmcid: 7946996
doi: 10.3389/fmicb.2021.615165
McAllister, N. et al. Chikungunya virus strains from each genetic clade bind sulfated glycosaminoglycans as attachment factors. J. Virol. 94, e01500-20 (2020).
pubmed: 32999033
pmcid: 7925169
doi: 10.1128/JVI.01500-20
Clark, L. E. et al. Abraham J. VLDLR and ApoER2 are receptors for multiple alphaviruses. Nature 602, 475–480 (2022).
pubmed: 34929721
doi: 10.1038/s41586-021-04326-0
Ma, H. et al. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature 588, 308–314 (2020).
pubmed: 33208938
pmcid: 7769003
doi: 10.1038/s41586-020-2915-3
Fongsaran, C. et al. Involvement of ATP synthase β subunit in chikungunya virus entry into insect cells. Arch. Virol. 159, 3353–3364 (2014).
pubmed: 25168043
doi: 10.1007/s00705-014-2210-4
Ghosh, A., Desai, A., Ravi, V., Narayanappa, G. & Tyagi, B. K. Chikungunya virus interacts with heat shock cognate 70 protein to facilitate its entry into mosquito cell line. Intervirology 60, 247–262 (2017).
pubmed: 29953983
doi: 10.1159/000489308
MacDonald, G. H. & Johnston, R. E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74, 914–922 (2000).
pubmed: 10623754
pmcid: 111612
doi: 10.1128/JVI.74.2.914-922.2000
Rudolph, K. E., Lessler, J., Moloney, R. M., Kmush, B. & Cummings, D. A. Incubation periods of mosquito-borne viral infections: a systematic review. Am. J. Trop. Med. Hyg. 90, 882–891 (2014).
pubmed: 24639305
pmcid: 4015582
doi: 10.4269/ajtmh.13-0403
Waggoner, J. J. et al. Viremia and clinical presentation in nicaraguan patients infected with Zika virus, Chikungunya virus, and Dengue virus. Clin. Infect. Dis. 63, 1584–1590 (2016).
pubmed: 27578819
pmcid: 5146717
doi: 10.1093/cid/ciw589
Matusali, G. et al. Tropism of the Chikungunya virus. Viruses 11, 175 (2019).
pubmed: 30791607
pmcid: 6410217
doi: 10.3390/v11020175
Pingen, M. et al. Host inflammatory response to mosquito bites enhances the severity of Arbovirus infection. Immunity 44, 1455–1469 (2016).
pubmed: 27332734
pmcid: 4920956
doi: 10.1016/j.immuni.2016.06.002
Thangamani, S. et al. Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus. PLoS ONE 5, e12137 (2010).
pubmed: 20711354
pmcid: 2920837
doi: 10.1371/journal.pone.0012137
Broeckel, R., Haese, N., Messaoudi, I. & Streblow, D. N. Nonhuman primate models of Chikungunya virus infection and disease (CHIKV NHP model). Pathogens 4, 662–681 (2015).
pubmed: 26389957
pmcid: 4584280
doi: 10.3390/pathogens4030662
Labadie, K. et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120, 894–906 (2010). This paper describes a macaque infection model that recapitulates the viral, clinical and pathological features observed in human CHIKV disease. The study identified macrophages as the main cellular reservoirs during the late stages of CHIKV infection in vivo.
pubmed: 20179353
pmcid: 2827953
doi: 10.1172/JCI40104
Lentscher, A. J. et al. Chikungunya virus replication in skeletal muscle cells is required for disease development. J. Clin. Invest. 130, 1466–1478 (2020).
pubmed: 31794434
pmcid: 7269570
doi: 10.1172/JCI129893
Haese, N. N. et al. Animal models of Chikungunya virus infection and disease. J. Infect. Dis. 214, S482–S487 (2016).
pubmed: 27920178
pmcid: 5137241
doi: 10.1093/infdis/jiw284
Ruiz Silva, M., van der Ende-Metselaar, H., Mulder, H. L., Smit, J. M. & Rodenhuis-Zybert, I. A. Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. Sci. Rep. 6, 32288 (2016).
pubmed: 27558873
pmcid: 4997611
doi: 10.1038/srep32288
Her, Z. et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J. Immunol. 184, 5903–5913 (2010).
pubmed: 20404274
doi: 10.4049/jimmunol.0904181
Ozden, S. et al. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS ONE 2, e527 (2007).
pubmed: 17565380
pmcid: 1885285
doi: 10.1371/journal.pone.0000527
Lohachanakul, J. et al. Differences in response of primary human myoblasts to infection with recent epidemic strains of Chikungunya virus isolated from patients with and without myalgia. J. Med. Virol. 87, 733–739 (2015).
pubmed: 25656089
doi: 10.1002/jmv.24081
Rohatgi, A. et al. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus. J. Virol. 88, 2414–2425 (2014).
pubmed: 24335291
pmcid: 3958092
doi: 10.1128/JVI.02716-13
Hoarau, J. J. et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J. Immunol. 184, 5914–5927 (2010).
pubmed: 20404278
doi: 10.4049/jimmunol.0900255
Young, A. R. et al. Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA. PLoS Pathog. 15, e1007993 (2019).
pubmed: 31465513
pmcid: 6715174
doi: 10.1371/journal.ppat.1007993
Suhrbier, A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat. Rev. Rheumatol. 15, 597–611 (2019). This review paper discusses the most current concepts of CHIKV-related rheumatic manifestations.
pubmed: 31481759
doi: 10.1038/s41584-019-0276-9
Roy, E., Shi, W., Duan, B. & Reid, S. P. Chikungunya virus infection impairs the function of osteogenic cells. mSphere 5, e00347-20 (2020).
pubmed: 32493723
pmcid: 7273349
doi: 10.1128/mSphere.00347-20
Chen, W. et al. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc. Natl Acad. Sci. USA 111, 6040–6045 (2014).
pubmed: 24733914
pmcid: 4000821
doi: 10.1073/pnas.1318859111
Amaral, J. K., Bilsborrow, J. B. & Schoen, R. T. Chronic Chikungunya arthritis and rheumatoid arthritis: what they have in common. Am. J. Med. 133, e91–e97 (2020).
pubmed: 31705850
doi: 10.1016/j.amjmed.2019.10.005
Chang, A. Y. et al. Chikungunya arthritis mechanisms in the Americas: a cross-sectional analysis of chikungunya arthritis patients twenty-two months after infection demonstrating no detectable viral persistence in synovial fluid. Arthritis Rheumatol. 70, 585–593 (2018).
pubmed: 29266856
pmcid: 8127625
doi: 10.1002/art.40383
Raghavendhar, B. S. et al. Virus load and clinical features during the acute phase of Chikungunya infection in children. PLoS ONE 14, e0211036 (2019).
doi: 10.1371/journal.pone.0211036
Dutta, S. K., Pal, T., Saha, B., Mandal, S. & Tripathi, A. Copy number variation of Chikungunya ECSA virus with disease symptoms among Indian patients. J. Med. Virol. 86, 1386–1392 (2014).
pubmed: 24132555
doi: 10.1002/jmv.23794
Paul, B. J. & Sadanand, S. Chikungunya infection: a re-emerging epidemic. Rheumatol. Ther. 5, 317–326 (2018).
pubmed: 30047016
pmcid: 6251852
doi: 10.1007/s40744-018-0121-7
Chhabra, M., Mittal, V., Bhattacharya, D., Rana, U. & Lal, S. Chikungunya fever: a re-emerging viral infection. Indian J. Med. Microbiol. 26, 5–12 (2008).
pubmed: 18227590
doi: 10.1016/S0255-0857(21)01984-8
Couderc, T. et al. A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 4, e29 (2008).
pubmed: 18282093
pmcid: 2242832
doi: 10.1371/journal.ppat.0040029
Win, M. K., Chow, A., Dimatatac, F., Go, C. J. & Leo, Y. S. Chikungunya fever in Singapore: acute clinical and laboratory features, and factors associated with persistent arthralgia. J. Clin. Virol. 49, 111–114 (2010).
pubmed: 20674479
doi: 10.1016/j.jcv.2010.07.004
Appassakij, H., Khuntikij, P., Kemapunmanus, M., Wutthanarungsan, R. & Silpapojakul, K. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 53, 2567–2574 (2013).
pubmed: 23176378
doi: 10.1111/j.1537-2995.2012.03960.x
Lanciotti, R. S. et al. Chikungunya virus in US travelers returning from India, 2006. Emerg. Infect. Dis. 13, 764–767 (2007).
pubmed: 17553261
pmcid: 2738459
doi: 10.3201/eid1305.070015
Laurent, P. et al. Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus. Clin. Chem. 53, 1408–1414 (2007).
pubmed: 17586592
doi: 10.1373/clinchem.2007.086595
Parola, P. et al. Novel Chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg. Infect. Dis. 12, 1493–1499 (2006).
pubmed: 17176562
pmcid: 3290960
doi: 10.3201/eid1210.060610
Gardner, J. et al. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84, 8021–8032 (2010).
pubmed: 20519386
pmcid: 2916516
doi: 10.1128/JVI.02603-09
Chow, A. et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J. Infect. Dis. 203, 149–157 (2011).
pubmed: 21288813
pmcid: 3071069
doi: 10.1093/infdis/jiq042
Noret, M. et al. Interleukin 6, RANKL, and osteoprotegerin expression by Chikungunya virus-infected human osteoblasts. J. Infect. Dis. 206, 455–457 (2012).
pubmed: 22634878
doi: 10.1093/infdis/jis368
Sharp, T. M. et al. Clinical characteristics, histopathology, and tissue immunolocalization of Chikungunya virus antigen in fatal cases. Clin. Infect. Dis. 73, e345–e354 (2021).
pubmed: 32615591
doi: 10.1093/cid/ciaa837
Economopoulou, A. et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion. Epidemiol. Infect. 137, 534–541 (2009).
pubmed: 18694529
doi: 10.1017/S0950268808001167
Tandale, B. V. et al. Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. J. Clin. Virol. 46, 145–149 (2009).
pubmed: 19640780
doi: 10.1016/j.jcv.2009.06.027
Das, S., Sarkar, N., Majumder, J., Chatterjee, K. & Aich, B. Acute disseminated encephalomyelitis in a child with chikungunya virus infection. J. Pediatr. Infect. Dis. 9, 37–41 (2014).
Mehta, R. et al. The neurological complications of chikungunya virus: a systematic review. Rev. Med. Virol. 28, e1978 (2018).
pubmed: 29671914
pmcid: 5969245
doi: 10.1002/rmv.1978
Maity, P., Roy, P., Basu, A., Das, B. & Ghosh, U. S. A case of ADEM following Chikungunya fever. J. Assoc. Physicians India 62, 441–442 (2014).
pubmed: 25438499
Ganesan, K. et al. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. Am. J. Neuroradiol. 29, 1636–1637 (2008).
pubmed: 18566010
pmcid: 8118764
doi: 10.3174/ajnr.A1133
Gérardin, P. et al. Chikungunya virus-associated encephalitis: a cohort study on La Réunion Island, 2005-2009. Neurology 86, 94–102 (2016).
pubmed: 26609145
doi: 10.1212/WNL.0000000000002234
Inglis, F. M. et al. Neuropathogenesis of Chikungunya infection: astrogliosis and innate immune activation. J. Neurovirol. 22, 140–148 (2016).
pubmed: 26419894
doi: 10.1007/s13365-015-0378-3
Kashyap, R. S. et al. Determination of Toll-like receptor-induced cytokine profiles in the blood and cerebrospinal fluid of Chikungunya patients. Neuroimmunomodulation 21, 338–346 (2014).
pubmed: 24776821
doi: 10.1159/000358240
da Silva, L. C. M. et al. Ocular manifestations of chikungunya infection: a systematic review. Pathogens 11, 412 (2022).
pubmed: 35456087
pmcid: 9028588
doi: 10.3390/pathogens11040412
Salceanu, S. O. & Raman, V. Recurrent chikungunya retinitis. BMJ Case Rep. 2018, bcr2017222864 (2018).
pubmed: 30150331
pmcid: 6119402
doi: 10.1136/bcr-2017-222864
Scripsema, N. K., Sharifi, E., Samson, C. M., Kedhar, S. & Rosen, R. B. Chikungunya-associated uveitis and exudative retinal detachment: a case report. Retinal Cases Brief. Rep. 9, 352–356 (2015).
doi: 10.1097/ICB.0000000000000232
Babu, K., Kini, R., Philips, M. & Subbakrishna, D. K. Clinical profile of isolated viral anterior uveitis in a South Indian patient population. Ocul. Immunol. Inflamm. 22, 356–359 (2014).
pubmed: 24111839
doi: 10.3109/09273948.2013.841482
Borgherini, G. et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin. Infect. Dis. 44, 1401–1407 (2007).
pubmed: 17479933
doi: 10.1086/517537
Lee, V. J. et al. Simple clinical and laboratory predictors of Chikungunya versus dengue infections in adults. PLoS Negl. Trop. Dis. 6, e1786 (2012).
pubmed: 23029573
pmcid: 3459852
doi: 10.1371/journal.pntd.0001786
Silva, J. V. J. et al. A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta Tropica 188, 213–224 (2018).
pubmed: 30195666
pmcid: 7092809
doi: 10.1016/j.actatropica.2018.09.003
Simon, F. et al. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Méd. Mal. Infect. 45, 243–263 (2015). Comprehensive guidelines for the clinical management of CHIKV infection.
pubmed: 26119684
doi: 10.1016/j.medmal.2015.05.007
Chopra, A., Anuradha, V., Ghorpade, R. & Saluja, M. Acute Chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural community study. Epidemiol. Infect. 140, 842–850 (2012).
pubmed: 21767452
doi: 10.1017/S0950268811001300
Heath, C. J. et al. The identification of risk factors for chronic Chikungunya Arthralgia in Grenada, West Indies: a cross-sectional cohort study. Open Forum Infect. Dis. 5, ofx234 (2018).
pubmed: 29308412
pmcid: 5753193
doi: 10.1093/ofid/ofx234
Sissoko, D. et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl. Trop. Dis. 3, e389 (2009).
pubmed: 19274071
pmcid: 2647734
doi: 10.1371/journal.pntd.0000389
Manimunda, S. P. et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans. R. Soc. Trop. Med. Hyg. 104, 392–399 (2010).
pubmed: 20171708
doi: 10.1016/j.trstmh.2010.01.011
Rodríguez-Morales, A. J., Cardona-Ospina, J. A., Fernanda Urbano-Garzón, S. & Sebastian Hurtado-Zapata, J. Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res. 68, 1849–1858 (2016).
doi: 10.1002/acr.22900
Ganu, M. A. & Ganu, A. S. Post-chikungunya chronic arthriti–our experience with DMARDs over two year follow up. J. Assoc. Physicians India 59, 83–86 (2011).
pubmed: 21751641
Contopoulos-Ioannidis, D., Newman-Lindsay, S., Chow, C. & LaBeaud, A. D. Mother-to-child transmission of Chikungunya virus: a systematic review and meta-analysis. PLoS Negl. Trop. Dis. 12, e0006510 (2018). This systematic review provides a comprehensive overview of the risk for mother-to-child transmission, antepartum fetal deaths, symptomatic neonatal disease and neonatal deaths from maternal CHIKV infections during gestation.
pubmed: 29897898
pmcid: 6075784
doi: 10.1371/journal.pntd.0006510
Gérardin, P. et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. PLoS Med. 5, e60 (2008).
pubmed: 18351797
pmcid: 2267812
doi: 10.1371/journal.pmed.0050060
Fritel, X. et al. Chikungunya virus infection during pregnancy, Reunion, France, 2006. Emerg. Infect. Dis. 16, 418–425 (2010).
pubmed: 20202416
pmcid: 3322036
doi: 10.3201/eid1604.091403
Foeller, M. E. et al. Chikungunya infection in pregnancy–reassuring maternal and perinatal outcomes: a retrospective observational study. BJOG 128, 1077–1086 (2021).
pubmed: 33040457
doi: 10.1111/1471-0528.16562
Touret, Y. et al. Early maternal-fetal transmission of the Chikungunya virus [French]. Presse Med. 35, 1656–1658 (2006).
pubmed: 17086120
doi: 10.1016/S0755-4982(06)74874-6
Gérardin, P. et al. Neurocognitive outcome of children exposed to perinatal mother-to-child Chikungunya virus infection: the CHIMERE cohort study on Reunion Island. PLoS Negl. Trop. Dis. 8, e2996 (2014).
pubmed: 25033077
pmcid: 4102444
doi: 10.1371/journal.pntd.0002996
PAHO. Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika (Pan American Health Organization, 2022).
WHO. Chikungunya fact sheet. WHO http://www.who.int/mediacentre/factsheets/fs327/en/ (2016).
CDC. Chikungunya virus. CDC http://www.cdc.gov/chikungunya/geo/index.html (2022).
Johnson, B. W., Russell, B. J. & Goodman, C. H. Laboratory diagnosis of Chikungunya virus infections and commercial sources for diagnostic assays. J. Infect. Dis. 214, S471–S474 (2016).
pubmed: 27920176
doi: 10.1093/infdis/jiw274
Natrajan, M. S., Rojas, A. & Waggoner, J. J. Beyond fever and pain: diagnostic methods for chikungunya virus. J. Clin. Microbiol. 57, e00350-19 (2019).
pubmed: 30995993
pmcid: 6535601
doi: 10.1128/JCM.00350-19
The International Diagnostics Center. Chikungunya virus infection diagnostics landscape 2017. The International Diagnostics Center https://idc-dx.net/resource/chikungunya-virus-infection-diagnostics-landscape-2017 (2019).
Patel, P. et al. A field-deployable reverse transcription recombinase polymerase amplification assay for rapid detection of the Chikungunya virus. PLoS Negl. Trop. Dis. 10, e0004953 (2016).
pubmed: 27685649
pmcid: 5042537
doi: 10.1371/journal.pntd.0004953
Karlikow, M. et al. Field validation of the performance of paper-based tests for the detection of the Zika and chikungunya viruses in serum samples. Nat. Biomed. Eng. 6, 246–256 (2022).
pubmed: 35256758
pmcid: 8940623
doi: 10.1038/s41551-022-00850-0
Moreira, J., Brasil, P., Dittrich, S. & Siqueira, A. M. Mapping the global landscape of chikungunya rapid diagnostic tests: a scoping review. PLoS Negl. Trop. Dis. 16, e0010067 (2022). This paper maps the global availability of CHIKV RDTs and evaluates their accuracy for the diagnosis of CHIKV.
pubmed: 35878158
pmcid: 9352193
doi: 10.1371/journal.pntd.0010067
Boeras, D. et al. Evaluation of Zika rapid tests as aids for clinical diagnosis and epidemic preparedness. EClinicalMedicine 49, 101478 (2022).
pubmed: 35747186
pmcid: 9167860
doi: 10.1016/j.eclinm.2022.101478
Prat, C. M. et al. Evaluation of commercially available serologic diagnostic tests for chikungunya virus. Emerg. Infect. Dis. 20, 2129–2132 (2014).
pubmed: 25418184
pmcid: 4257799
doi: 10.3201/eid2012.141269
Fischer, C. et al. Robustness of serologic investigations for Chikungunya and Mayaro viruses following Coemergence. mSphere 5, e00915-19 (2020).
pubmed: 32024703
pmcid: 7002312
doi: 10.1128/mSphere.00915-19
Lima, M. D. R. Q., de Lima, R. C., de Azeredo, E. L. & Dos Santos, F. B. Analysis of a routinely used commercial anti-Chikungunya IgM ELISA reveals cross-reactivities with Dengue in Brazil: a new challenge for differential diagnosis? Diagnostics 11, 819 (2021).
pubmed: 33946597
pmcid: 8147240
doi: 10.3390/diagnostics11050819
Harrison, V. R., Binn, L. N. & Randall, R. Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am. J. Trop. Med. Hyg. 16, 786–791 (1967).
pubmed: 4965219
doi: 10.4269/ajtmh.1967.16.786
Harrison, V. R., Eckels, K. H., Bartelloni, P. J. & Hampton, C. Production and evaluation of a formalin-killed Chikungunya vaccine. J. Immunol. 107, 643–647 (1971).
pubmed: 4999088
doi: 10.4049/jimmunol.107.3.643
Reyes-Sandoval, A. 51 years in of Chikungunya clinical vaccine development: a historical perspective. Hum. Vaccin. Immunother. 15, 2351–2358 (2019). This review provides a very complete overview of the development of CHIKV vaccines that have reached the stage of clinical trials since the late 1960s up until 2018.
pubmed: 30735447
pmcid: 6816471
doi: 10.1080/21645515.2019.1574149
Valneva. Valneva initiates rolling submission of FDA biologics license application for its single-shot Chikungunya vaccine candidate. Valneva https://valneva.com/press-release/valneva-initiates-rolling-submission-of-fda-biologics-license-application-for-its-single-shot-chikungunya-vaccine-candidate/ (2022).
International Vaccine Institute. Chikungunya: advancing the world’s first Chikungunya vaccine. International Vaccine Institute https://www.ivi.int/what-we-do/disease-areas/chikungunya/ (2021).
Chen, R. et al. Comprehensive genome scale phylogenetic study provides new insights on the global expansion of chikungunya virus. J. Virol. 90, 10600–10611 (2016).
pubmed: 27654297
pmcid: 5110187
doi: 10.1128/JVI.01166-16
Katzelnick, L. C. et al. Antigenic evolution of dengue viruses over 20 years. Science 374, 999–1004 (2021).
pubmed: 34793238
pmcid: 8693836
doi: 10.1126/science.abk0058
Milligan, G. N., Schnierle, B. S., McAuley, A. J. & Beasley, D. W. C. Defining a correlate of protection for chikungunya virus vaccines. Vaccine 37, 7427–7436 (2019). This report reviews the current status of non-clinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection for CHIKV.
pubmed: 30448337
doi: 10.1016/j.vaccine.2018.10.033
Thompson, D., Metz, S. W., Abad, C., Beaty, S. & Warfield, K. Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines. Vaccine 40, 3009–3017 (2022).
pubmed: 35459557
doi: 10.1016/j.vaccine.2022.04.021
Kam, Y. W. et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J. Virol. 86, 13005–13015 (2012).
pubmed: 23015702
pmcid: 3497641
doi: 10.1128/JVI.01780-12
Verma, P. et al. Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis. Clin. Chem. Lab. Med. 52, 297–307 (2014).
pubmed: 24088615
doi: 10.1515/cclm-2013-0363
Kam, Y. W. et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 4, 330–343 (2012).
pubmed: 22389221
pmcid: 3376860
doi: 10.1002/emmm.201200213
Henss, L. et al. Analysis of humoral immune responses in chikungunya virus (CHIKV)-infected patients and individuals vaccinated with a candidate CHIKV vaccine. J. Infect. Dis. 221, 1713–1723 (2020).
pubmed: 31828322
doi: 10.1093/infdis/jiz658
Kam, Y. W. et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 205, 1147–1154 (2012).
pubmed: 22389226
pmcid: 3295607
doi: 10.1093/infdis/jis033
Galatas, B. et al. Long-lasting immune protection and other epidemiological findings after Chikungunya emergence in a Cambodian Rural Community, April 2012. PLoS Negl. Trop. Dis. 10, e0004281 (2016).
pubmed: 26752630
pmcid: 4713465
doi: 10.1371/journal.pntd.0004281
Nitatpattana, N. et al. Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virol. J. 11, 183 (2014).
pubmed: 25330992
pmcid: 4283153
doi: 10.1186/1743-422X-11-183
Valneva. Valneva reports positive end-of-phase 2 Chikungunya meeting with the U.S. FDA; sets stage for phase 3 study. Valneva https://valneva.com/press-release/valneva-reports-positive-end-of-phase-2-chikungunya-meeting-with-the-u-s-fda-sets-stage-for-phase-3-study/ (2020).
Valneva. Valneva completes BLA submission to U.S. FDA for its single-shot chikungunya vaccine candidate. Valneva https://valneva.com/press-release/valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate/ (2022).
Levitt, N. H. et al. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4, 157–162 (1986).
pubmed: 3020820
doi: 10.1016/0264-410X(86)90003-4
McClain, D. J. et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J. Infect. Dis. 177, 634–641 (1998).
pubmed: 9498442
doi: 10.1086/514240
Edelman, R. et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681–685 (2000).
pubmed: 11304054
doi: 10.4269/ajtmh.2000.62.681
Roques, P. et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2, e83527 (2017).
pubmed: 28352649
pmcid: 5358498
doi: 10.1172/jci.insight.83527
Wressnigg, N. et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect. Dis. 20, 1193–1203 (2020).
pubmed: 32497524
doi: 10.1016/S1473-3099(20)30238-3
Roques, P. et al. Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. JCI Insight 7, e160173 (2022). This study evaluated the effectiveness of the live-attenuated CHIKV vaccine VLA1553 against wild-type CHIKV infection by using passive transfer of sera from vaccinated volunteers to non-human primates subsequently exposed to wild-type CHIKV and established a serological surrogate of protection. The study demonstrated that human VLA1553 sera transferred to non-human primates conferred complete protection from CHIKV viraemia and fever after challenge with homologous wild-type CHIKV and that serum transfer protected animals from other CHIKV-associated clinical symptoms and from CHIKV persistence in tissue.
pubmed: 35700051
pmcid: 9431671
doi: 10.1172/jci.insight.160173
Mohsen, M. O. & Bachmann, M. F. Virus-like particle vaccinology, from bench to bedside. Cell Mol. Immunol. 19, 993–1011 (2022).
pubmed: 35962190
pmcid: 9371956
doi: 10.1038/s41423-022-00897-8
Chang, L. J. et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384, 2046–2052 (2014).
pubmed: 25132507
doi: 10.1016/S0140-6736(14)61185-5
Goo, L. et al. A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes. J. Infect. Dis. 214, 1487–1491 (2016).
pubmed: 27655868
pmcid: 5091377
doi: 10.1093/infdis/jiw431
Bennett, S. R. et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect. Dis. 22, 1343–1355 (2022). This paper reports on a randomized, double-blind, parallel-group, phase II trial evaluating the safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted formulation of a CHIKV VLP vaccine.
pubmed: 35709798
doi: 10.1016/S1473-3099(22)00226-2
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT05072080 (2022).
PRNewswire. FDA grants PaxVax fast track designation for its Chikungunya vaccine. PRNewswire https://www.prnewswire.com/news-releases/fda-grants-paxvax-fast-track-designation-for-its-chikungunya-vaccine-300642602.html (2018).
Reisinger, E. C. et al. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392, 2718–2727 (2019).
pubmed: 30409443
doi: 10.1016/S0140-6736(18)32488-7
Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519–527 (2015).
pubmed: 25739878
doi: 10.1016/S1473-3099(15)70043-5
Brandler, S. et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31, 3718–3725 (2013).
pubmed: 23742993
doi: 10.1016/j.vaccine.2013.05.086
Rossi, S. L. et al. Immunogenicity and efficacy of a measles virus-vectored Chikungunya vaccine in nonhuman primates. J. Infect. Dis. 220, 735–742 (2019).
pubmed: 31053842
pmcid: 6667792
doi: 10.1093/infdis/jiz202
Themis Bioscience GmbH. Vaccines and related biological products advisory committee meeting: 08 November 2019: Themis company briefing document. Themis Bioscience GmbH https://fda.report/media/132288/VRBPAC-11.08.19-Meeting-Briefing-Document-Sponsor.pdf (2019).
businesswire. Themis Bioscience receives FDA fast track designation for Chikungunya vaccine candidate. businesswire https://www.businesswire.com/news/home/20190225005236/en/Themis-Bioscience-Receives-FDA-Fast-Track-Designation-for-Chikungunya-Vaccine-Candidate (2019).
European Medicines Agency. List of medicines currently in PRIME scheme. EMA https://www.ema.europa.eu/documents/report/list-products-granted-eligibility-prime_en-0.xlsx (2023).
CEPI. CEPI awards up to US$21 million to Themis Bioscience for phase 3 Chikungunya vaccine development. CEPI https://cepi.net/news_cepi/cepi-awards-up-to-us21-million-to-themis-bioscience-for-phase-3-chikungunya-vaccine-development/ (2019).
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03807843 (2022).
US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT03101111 (2021).
Tiwari, M. et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27, 2513–2522 (2009).
pubmed: 19368794
doi: 10.1016/j.vaccine.2009.02.062
CEPI. CEPI awards up to US$14.1 million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI. CEPI https://cepi.net/news_cepi/cepi-awards-up-to-us-14-1-million-to-consortium-of-ivi-and-bharat-biotech-to-advance-development-of-chikungunya-vaccine-in-collaboration-with-ind-cepi/ (2020).
Shaw, C. et al. Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial. Int. J. Infect. Dis. 79, 17 (2019).
doi: 10.1016/j.ijid.2018.11.058
United States Securities and Exchange Commission. Moderna Inc. United States Securities and Exchange Commission https://www.sec.gov/Archives/edgar/data/1682852/000168285219000009/moderna10-k12312018.htm (2018).
Folegatti, P. M. et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat. Commun. 12, 4636 (2021).
pubmed: 34330906
pmcid: 8324904
doi: 10.1038/s41467-021-24906-y
Wang, E., Kim, D. Y., Weaver, S. C. & Frolov, I. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J. Virol. 85, 9249–9252 (2011).
pubmed: 21697494
pmcid: 3165793
doi: 10.1128/JVI.00844-11
Erasmus, J. H. et al. Utilization of an Eilat virus-based chimera for serological detection of Chikungunya infection. PLoS Negl. Trop. Dis. 9, e0004119 (2015).
pubmed: 26492074
pmcid: 4619601
doi: 10.1371/journal.pntd.0004119
Chattopadhyay, A., Wang, E., Seymour, R., Weaver, S. C. & Rose, J. K. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J. Virol. 87, 395–402 (2013).
pubmed: 23077320
pmcid: 3536361
doi: 10.1128/JVI.01860-12
van den Doel, P. et al. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl. Trop. Dis. 8, e3101 (2014).
pubmed: 25188230
pmcid: 4154657
doi: 10.1371/journal.pntd.0003101
García-Arriaza, J. et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J. Virol. 88, 3527–3547 (2014).
pubmed: 24403588
pmcid: 3957920
doi: 10.1128/JVI.03418-13
Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019).
pubmed: 31101672
pmcid: 6629435
doi: 10.1126/sciimmunol.aaw6647
August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224–2233 (2021).
pubmed: 34887572
pmcid: 8674127
doi: 10.1038/s41591-021-01573-6
Wahid, B., Ali, A., Rafique, S. & Idrees, M. Global expansion of chikungunya virus: mapping the 64-year history. Int. J. Infect. Dis. 58, 69–76 (2017).
pubmed: 28288924
doi: 10.1016/j.ijid.2017.03.006
Perich, M. J., Davila, G., Turner, A., Garcia, A. & Nelson, M. Behavior of resting Aedes aegypti (Culicidae: Diptera) and its relation to ultra-low volume adulticide efficacy in Panama City, Panama. J. Med. Entomol. 37, 541–546 (2000).
pubmed: 10916294
doi: 10.1603/0022-2585-37.4.541
Barrera, R. New tools for Aedes control: mass trapping. Curr. Opin. Insect Sci. 52, 100942 (2022).
pubmed: 35667560
doi: 10.1016/j.cois.2022.100942
Juarez, J. G. et al. Variable coverage in an autocidal gravid ovitrap intervention impacts efficacy of Aedes aegypti control. J. Appl. Ecol. 58, 2075–2086 (2021).
pubmed: 34690360
pmcid: 8518497
doi: 10.1111/1365-2664.13951
Sippy, R. et al. Ingested insecticide to control Aedes aegypti: developing a novel dried attractive toxic sugar bait device for intra-domiciliary control. Parasit. Vectors 13, 78 (2020).
pubmed: 32066486
pmcid: 7027216
doi: 10.1186/s13071-020-3930-9
Tambwe, M. M. et al. Semi-field evaluation of the exposure-free mosquito electrocuting trap and BG-Sentinel trap as an alternative to the human landing catch for measuring the efficacy of transfluthrin emanators against Aedes aegypti. Parasit. Vectors 14, 265 (2021).
pubmed: 34016149
pmcid: 8138975
doi: 10.1186/s13071-021-04754-x
Hapairai, L. K. et al. Evaluation of large volume yeast interfering RNA lure-and-kill ovitraps for attraction and control of Aedes mosquitoes. Med. Vet. Entomol. 35, 361–370 (2021).
pubmed: 33377553
doi: 10.1111/mve.12504
Leandro, A. S. et al. Citywide integrated Aedes aegypti mosquito surveillance as early warning system for arbovirus transmission, Brazil. Emerg. Infect. Dis. 28, 701–706 (2022).
pubmed: 35318912
doi: 10.3201/eid2804.211547
Wang, G. H. et al. Combating mosquito-borne diseases using genetic control technologies. Nat. Commun. 12, 4388 (2021).
pubmed: 34282149
pmcid: 8290041
doi: 10.1038/s41467-021-24654-z
Antunes de Brito, C. A. et al. Pharmacologic management of pain in patients with Chikungunya: a guideline. Rev. Soc. Bras. Med. Trop. 49, 668–679 (2016). Comprehensive guidelines for the clinical management of CHIKV infection.
doi: 10.1590/0037-8682-0279-2016
Webb, E. et al. An evaluation of global Chikungunya clinical management guidelines: a systematic review. eClinicalMedicine 54, 101672 (2022). The most recent comprehensive guidelines for the clinical management of CHIKV infection.
pubmed: 36193172
pmcid: 9526181
doi: 10.1016/j.eclinm.2022.101672
Scott, S. S. et al. Immunoglobulin-responsive chikungunya encephalitis: two case reports. J. Neurovirol. 23, 625–631 (2017).
pubmed: 28577289
doi: 10.1007/s13365-017-0535-y
Fernandes, A. I. V., Souza, J. R., Silva, A. R., Cruz, S. B. S. C. & Castellano, L. R. C. Immunoglobulin therapy in a patient with severe chikungunya fever and vesiculobullous lesions. Front. Immunol. 10, 1498 (2019).
pubmed: 31312203
pmcid: 6614379
doi: 10.3389/fimmu.2019.01498
Marques, C. D. L. et al. Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 — treatment. Rev. Bras. Reumatol. 57 (Suppl. 2), 438–451 (2017).
doi: 10.1016/j.rbr.2017.05.005
Zaid, A. et al. Chikungunya arthritis: implications of acute and chronic inflammation mechanisms on disease management. Arthritis Rheumatol. 70, 484–495 (2018).
pubmed: 29287308
doi: 10.1002/art.40403
Bouhassira, D. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114, 29–36 (2005).
pubmed: 15733628
doi: 10.1016/j.pain.2004.12.010
de Andrade, D. C., Jean, S., Clavelou, P., Dallel, R. & Bouhassira, D. Chronic pain associated with the Chikungunya fever: long lasting burden of an acute illness. BMC Infect. Dis. 10, 31 (2010).
pubmed: 20170492
pmcid: 2833164
doi: 10.1186/1471-2334-10-31
Graham, B. S., Repik, P. M. & Yactayo, S. Chikungunya in the Americas: recommendations and conclusions. J. Infect. Dis. 214, S510–S513 (2016).
pubmed: 27920183
pmcid: 5137245
doi: 10.1093/infdis/jiw370
Burt, F. J., Rolph, M. S., Rulli, N. E., Mahalingam, S. & Heise, M. T. Chikungunya: a re-emerging virus. Lancet 379, 662–671 (2012).
pubmed: 22100854
doi: 10.1016/S0140-6736(11)60281-X
WHO. Guidelines on clinical management of Chikungunya fever. WHO https://www.who.int/westernpacific/publications-detail/guidelines-on-clinical-management-of-chikungunya-fever (2019).
De Lamballerie, X. et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis. 8, 837–839 (2008).
pubmed: 18620511
doi: 10.1089/vbz.2008.0049
Kumar, R., Ahmed, S., Parray, H. A. & Das, S. Chikungunya and arthritis: an overview. Travel Med. Infect. Dis. 44, 102168 (2021).
pubmed: 34563686
doi: 10.1016/j.tmaid.2021.102168
Pitt Gameiro Sales, G. M. et al. Treatment of chikungunya chronic arthritis: a systematic review. Rev. Assoc. Med. Bras. 64, 63–70 (2018).
doi: 10.1590/1806-9282.64.01.63
Vairo, F. et al. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention. Infect. Dis. Clin. North Am. 33, 1003–1025 (2019).
pubmed: 31668189
doi: 10.1016/j.idc.2019.08.006
Pathak, H., Mohan, M. C. & Ravindran, V. Chikungunya arthritis. Clin. Med. 19, 381–385 (2019).
doi: 10.7861/clinmed.2019-0035
Bank, A. M., Batra, A., Colorado, R. A. & Lyons, J. L. Myeloradiculopathy associated with chikungunya virus infection. J. Neurovirol. 22, 125–128 (2016).
pubmed: 26306687
doi: 10.1007/s13365-015-0372-9
Simon, F., Javelle, E. & Gasque, P. Chikungunya virus infections. N. Engl. J. Med. 373, 93–94 (2015).
pubmed: 26132957
doi: 10.1056/NEJMc1505501
Radu, A.-F. & Bungau, S. G. Management of rheumatoid arthritis: an overview. Cells 10, 2857 (2021).
pubmed: 34831081
pmcid: 8616326
doi: 10.3390/cells10112857
Kennedy Amaral Pereira, J. & Schoen, R. T. Management of chikungunya arthritis. Clin. Rheumatol. 36, 2179–2186 (2017).
pubmed: 28776302
doi: 10.1007/s10067-017-3766-7
McHugh, J. Long-term effects of chikungunya. Nat. Rev. Rheumatol. 14, 62–62 (2018).
pubmed: 29362462
doi: 10.1038/nrrheum.2017.223
Javelle, E. et al. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. PLoS Negl. Trop. Dis. 9, e0003603 (2015).
pubmed: 25760632
pmcid: 4356515
doi: 10.1371/journal.pntd.0003603
Pandya, S. Methotrexate and hydroxychloroquine combination therapy in chronic chikungunya arthritis: a 16 week study. Indian J. Rheumatol. 3, 93–97 (2008).
doi: 10.1016/S0973-3698(10)60125-2
Faraone, I., Labanca, F., Ponticelli, M., De Tommasi, N. & Milella, L. Recent clinical and preclinical studies of hydroxychloroquine on RNA viruses and chronic diseases: a systematic review. Molecules 25, 5318 (2020).
pubmed: 33202656
pmcid: 7696151
doi: 10.3390/molecules25225318
Ravindran, V. & Alias, G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clin. Rheumatol. 36, 1335–1340 (2017).
pubmed: 27699657
doi: 10.1007/s10067-016-3429-0
Neumann, I. L. et al. Resistance exercises improve physical function in chronic Chikungunya fever patients: a randomized controlled trial. Eur. J. Phys. Rehabil. Med. 57, 620–629 (2021).
pubmed: 33448754
doi: 10.23736/S1973-9087.21.06520-5
Silva-Filho, E. et al. Neuromodulation treats Chikungunya arthralgia: a randomized controlled trial. Sci. Rep. 8, 16010 (2018).
pubmed: 30375485
pmcid: 6207669
doi: 10.1038/s41598-018-34514-4
Nascimento, A. S. D. et al. Ten sessions of transcranial direct current stimulation for chronic chikungunya arthralgia: study protocol for a randomised clinical trial. BMJ Open 12, e065387 (2022).
pubmed: 36288831
pmcid: 9615989
doi: 10.1136/bmjopen-2022-065387
Queyriaux, B. et al. Clinical burden of chikungunya virus infection. Lancet Infect. Dis. 8, 2–3 (2008).
pubmed: 18156079
doi: 10.1016/S1473-3099(07)70294-3
Crosby, L. et al. Severe manifestations of chikungunya virus in critically ill patients during the 2013-2014 Caribbean outbreak. Int. J. Infect. Dis. 48, 78–80 (2016).
pubmed: 27208636
doi: 10.1016/j.ijid.2016.05.010
Mercado, M. et al. Clinical and histopathological features of fatal cases with dengue and chikungunya virus co-infection in Colombia, 2014 to 2015. Eurosurveillance 21, 30244 (2016).
doi: 10.2807/1560-7917.ES.2016.21.22.30244
Ramachandran, V. et al. Impact of Chikungunya on health related quality of life Chennai, South India. PLoS ONE 7, e51519 (2012).
pubmed: 23251562
pmcid: 3520806
doi: 10.1371/journal.pone.0051519
Wei Chiam, C., Fun Chan, Y., Chai Ong, K., Thong Wong, K. & Sam, I. C. Neurovirulence comparison of chikungunya virus isolates of the Asian and East/Central/South African genotypes from Malaysia. J. Gen. Virol. 96, 3243–3254 (2015).
pubmed: 26276497
doi: 10.1099/jgv.0.000263
Doran, C. et al. The clinical manifestation and the influence of age and comorbidities on long-term chikungunya disease and health-related quality of life: a 60-month prospective cohort study in Curaçao. BMC Infect. Dis. 22, 948 (2022).
pubmed: 36526964
pmcid: 9756924
doi: 10.1186/s12879-022-07922-1
Lopes Marques, C. D. et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 — diagnosis and special situations. Rev. Bras. Reumatol. Engl. Ed. 57, 421–437 (2017).
Martõâ-Carvajal, A. et al. Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: a systematic review. PLoS ONE 12, e0179028 (2017).
doi: 10.1371/journal.pone.0179028
Watson, H. et al. Stiffness, pain, and joint counts in chronic chikungunya disease: relevance to disability and quality of life. Clin. Rheumatol. 39, 1679–1686 (2020).
pubmed: 31916107
pmcid: 7945009
doi: 10.1007/s10067-019-04919-1
Doran, C. et al. Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao. PLoS Negl. Trop. Dis. 16, e0010142 (2022).
pubmed: 35231033
pmcid: 8887759
doi: 10.1371/journal.pntd.0010142
Marimoutou, C., Ferraro, J., Javelle, E., Deparis, X. & Simon, F. Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6 years later. Clin. Microbiol. Infect. 21, 688–693 (2015).
pubmed: 25752222
doi: 10.1016/j.cmi.2015.02.024
Venter, M. Assessing the zoonotic potential of arboviruses of African origin. Curr. Opin. Virol. 28, 74–84 (2018).
pubmed: 29216533
doi: 10.1016/j.coviro.2017.11.004
Rezza, G., Chen, R. & Weaver, S. C. O’nyong-nyong fever: a neglected mosquito-borne viral disease. Pathog. Glob. Health 111, 271–275 (2017).
pubmed: 28829253
pmcid: 5694854
doi: 10.1080/20477724.2017.1355431
Weaver, S. C., Charlier, C., Vasilakis, N. & Lecuit, M. Zika, Chikungunya, and other emerging vector-borne viral diseases. Annu. Rev. Med. 69, 395–408 (2018).
pubmed: 28846489
doi: 10.1146/annurev-med-050715-105122
Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E. & Halstead, S. B. Dengue infection. Nat. Rev. Dis. Primers 2, 16055 (2016).
pubmed: 27534439
doi: 10.1038/nrdp.2016.55
Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123–1128 (2020).
pubmed: 32855339
pmcid: 8274975
doi: 10.1126/science.abb6143
Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).
pubmed: 29097492
pmcid: 5858873
doi: 10.1126/science.aan6836
Kam, Y. W. et al. Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl. Trop. Dis. 9, e3445 (2015).
pubmed: 25568956
pmcid: 4287563
doi: 10.1371/journal.pntd.0003445
Torres-Ruesta, A., Chee, R. S. & Ng, L. F. P. Insights into antibody-mediated alphavirus immunity and vaccine development landscape. Microorganisms 9, 899 (2021).
pubmed: 33922370
pmcid: 8145166
doi: 10.3390/microorganisms9050899
Babaeimarzangou, S. S. et al. Vaccine development for zoonotic viral diseases caused by positive-sense single-stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review). Exp. Ther. Med. 25, 42 (2022).
pubmed: 36569444
pmcid: 9768462
doi: 10.3892/etm.2022.11741
WHO. WHO consultation on Chikungunya vaccine evaluation. WHO https://www.who.int/docs/default-source/blue-print/chikungunya-vaccines-workshop-29-november-2018.pdf?sfvrsn=7c40e201_2 (2018).
Malonis, R. J. et al. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Proc. Natl Acad. Sci. USA 118, e2100104118 (2021).
pubmed: 34507983
pmcid: 8449321
doi: 10.1073/pnas.2100104118
Zhou, Q. F. et al. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Proc. Natl Acad. Sci. USA 117, 27637–27645 (2020).
pubmed: 33087569
pmcid: 7959576
doi: 10.1073/pnas.2008051117
Kim, A. S. & Diamond, M. S. A molecular understanding of alphavirus entry and antibody protection. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00825-7 (2022). This review highlights recent advances in our understanding of the host factors required for alphavirus entry, the mechanisms of action by which protective antibodies inhibit different steps in the alphavirus infection cycle and candidate alphavirus vaccines currently under clinical evaluation that focus on humoral immunity.
doi: 10.1038/s41579-022-00825-7
pubmed: 36474012
pmcid: 9734810
Jin, J. & Simmons, G. Antiviral functions of monoclonal antibodies against Chikungunya virus. Viruses 11, 305 (2019).
pubmed: 30925717
pmcid: 6520934
doi: 10.3390/v11040305
Fox, J. M. et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163, 1095–1107 (2015).
pubmed: 26553503
pmcid: 4659373
doi: 10.1016/j.cell.2015.10.050
Abdelnabi, R. & Delang, L. Antiviral strategies against arthritogenic alphaviruses. Microorganisms 8, 1365 (2020). This article provides a complete overview of the reported antiviral strategies against arthritogenic alphaviruses and highlights future perspectives for the development and proper use of such antivirals.
pubmed: 32906603
pmcid: 7563460
doi: 10.3390/microorganisms8091365
Skidmore, A. M. & Bradfute, S. B. The life cycle of the alphaviruses: from an antiviral perspective. Antivir. Res. 209, 105476 (2023).
pubmed: 36436722
doi: 10.1016/j.antiviral.2022.105476
Battisti, V., Urban, E. & Langer, T. Antivirals against the Chikungunya virus. Viruses 13, 1307 (2021).
pubmed: 34372513
pmcid: 8310245
doi: 10.3390/v13071307
Tripathi, P. K. et al. Evaluation of novobiocin and telmisartan for anti-CHIKV activity. Virology 548, 250–260 (2020).
pubmed: 32791353
doi: 10.1016/j.virol.2020.05.010
Delang, L., Abdelnabi, R. & Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir. Res. 153, 85–94 (2018).
pubmed: 29524445
doi: 10.1016/j.antiviral.2018.03.003
Ferreira, A. C. et al. Beyond members of the flaviviridae family, sofosbuvir also inhibits Chikungunya virus replication. Antimicrob. Agents Chemother. 63, e01389-18 (2019).
pubmed: 30455237
pmcid: 6355571
doi: 10.1128/AAC.01389-18
Fox, J. M. et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcgammaR interaction on monocytes. Sci. Immunol. 4, eaav5062 (2019).
pubmed: 30796092
pmcid: 6698136
doi: 10.1126/sciimmunol.aav5062
WHO. Prioritizing diseases for research and development in emergency contexts. WHO https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts (2015).
Africa CDC. Risk ranking and prioritization of epidemic-prone diseases. Africa CDC https://africacdc.org/download/risk-ranking-and-prioritization-of-epidemic-prone-diseases/ (2023).
Kamal, M., Kenawy, M. A., Rady, M. H., Khaled, A. S. & Samy, A. M. Mapping the global potential distributions of two arboviral vectors Aedes aegypti and Ae. albopictus under changing climate. PLoS ONE 13, e0210122 (2018).
pubmed: 30596764
pmcid: 6312308
doi: 10.1371/journal.pone.0210122
Kraemer, M. U. G. et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat. Microbiol. 4, 854–863 (2019).
pubmed: 30833735
pmcid: 6522366
doi: 10.1038/s41564-019-0376-y
Swan, T. et al. A literature review of dispersal pathways of Aedes albopictus across different spatial scales: implications for vector surveillance. Parasit. Vectors 15, 303 (2022).
pubmed: 36030291
pmcid: 9420301
doi: 10.1186/s13071-022-05413-5
Oliveira, S., Rocha, J., Sousa, C. A. & Capinha, C. Wide and increasing suitability for Aedes albopictus in Europe is congruent across distribution models. Sci. Rep. 11, 9916 (2021).
pubmed: 33972597
pmcid: 8110805
doi: 10.1038/s41598-021-89096-5
ECDC. Mosquito maps. ECDC https://ecdc.europa.eu/en/disease-vectors/surveillance-and-disease-data/mosquito-maps (2023).
Strauss, E. G., Rice, C. M. & Strauss, J. H. Sequence coding for the alphavirus nonstructural proteins is interrupted by an opal termination codon. Proc. Natl Acad. Sci. USA 80, 5271–5275 (1983).
pubmed: 6577423
pmcid: 384235
doi: 10.1073/pnas.80.17.5271
Chen, K. C. et al. Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. Virol. J. 10, 169 (2013).
pubmed: 23721429
pmcid: 3679931
doi: 10.1186/1743-422X-10-169
Tanabe, I. S. B. et al. Cellular and molecular immune response to Chikungunya virus infection. Front. Cell Infect. Microbiol. 8, 345 (2018).
pubmed: 30364124
pmcid: 6191487
doi: 10.3389/fcimb.2018.00345
Ng, L. F. P. Immunopathology of Chikungunya virus infection: lessons learned from patients and animal models. Annu. Rev. Virol. 4, 413–427 (2017).
pubmed: 28637387
doi: 10.1146/annurev-virology-101416-041808